Drug Overview

Frisium (marketed as Onfi in the United States) is a highly specialized pharmaceutical agent within the field of Neurology. It belongs to the Benzodiazepine drug class, specifically the 1,5-benzodiazepine subclass, which distinguishes it chemically and pharmacologically from more common 1,4-benzodiazepines like diazepam or lorazepam.Frisium / Onfi

The primary clinical utility of this medication lies in its potent anticonvulsant properties. It is engineered to provide long-term seizure control while maintaining a more favorable side-effect profile regarding sedation compared to its predecessors. As an adjunctive therapy, it is integral to the management of refractory epilepsy, where standard first-line treatments have failed to achieve adequate seizure freedom.

Generic Name: Clobazam
US Brand Name: Onfi
International Brand Name: Frisium
Drug Class: 1,5-Benzodiazepine (Anticonvulsant)
Route of Administration: Oral (Available as tablets and oral suspension)
FDA Approval Status: Approved for the adjunctive treatment of seizures associated with Lennox-Gastaut Syndrome (LGS) in patients 2 years of age and older.
Controlled Substance Schedule: Schedule IV (CIV) in the United States.

What Is It and How Does It Work? (Mechanism of Actio

To understand how Frisium functions, one must look at the delicate balance of excitatory and inhibitory signals within the human Central Nervous System (CNS). In neurological conditions like epilepsy, there is an overabundance of excitatory signals or a deficiency in inhibitory signals, leading to the rapid, rhythmic firing of neurons that manifests as a seizure.

Clobazam operates as a Potentiator of Gamma-Aminobutyric Acid (GABA). GABA is the primary inhibitory neurotransmitter in the brain. Its role is to “calm” neuronal activity by binding to specific receptors and preventing the neuron from firing.

Molecular Mechanism: The GABA-A Receptor Complex

At the molecular level, Clobazam targets the GABA-A receptor, a ligand-gated ion channel. This receptor is composed of five subunits that form a central pore through which chloride ions (Cl⁻) can pass.

Allosteric Modulation: Unlike GABA itself, which binds to the alpha/beta interface of the receptor, Clobazam binds to an allosteric site (specifically the benzodiazepine site located at the interface of the alpha and gamma subunits).
Increased Chloride Conductance: When Clobazam binds to this site, it induces a conformational change in the receptor. This change increases the frequency with which the chloride channel opens in response to GABA.
Hyperpolarization: As the channel opens more frequently, a larger influx of negatively charged chloride ions enters the post-synaptic neuron. This causes the electrical potential of the cell to become more negative, a process known as hyperpolarization.
Seizure Threshold Elevation: Because the neuron is hyperpolarized, it becomes significantly harder for an excitatory signal to “trigger” the neuron into firing. By stabilizing the neuronal membrane in this way, Clobazam effectively raises the seizure threshold and prevents the spread of abnormal electrical discharges throughout the brain.

The 1,5-Benzodiazepine Advantage

Standard benzodiazepines (1,4-benzodiazepines) often bind indiscriminately to various GABA-A receptor subtypes, leading to heavy sedation. Clobazam’s 1,5-structure provides a more selective affinity for the alpha-2 subunit (associated with anti-seizure and anti-anxiety effects) over the alpha-1 subunit (associated with heavy sedation). This makes it a Targeted Therapy for seizure control with a potentially wider therapeutic window.

FDA-Approved Clinical Indications

Primary Indication: Lennox-Gastaut Syndrome (LGS)

The principal FDA-approved use for Frisium/Onfi is the adjunctive treatment of seizures associated with Lennox-Gastaut Syndrome (LGS) in pediatric and adult patients aged 2 years and older. LGS is a severe, childhood-onset epilepsy characterized by multiple seizure types—most notably “drop attacks” (atonic seizures)—and cognitive impairment. Because LGS is notoriously resistant to conventional medication, Clobazam is utilized as an “add-on” to an existing regimen to reduce the frequency of drop seizures.

Other Approved and Off-Label Uses

While LGS is the specific FDA-labeled indication, Clobazam is utilized globally for various neurological and psychiatric conditions:

Refractory Complex Partial Seizures: Used as an adjunct in patients who do not respond to primary anticonvulsants.
Myoclonic Seizures: Effective in reducing the sudden, brief “shocks” or muscle jerks associated with certain epilepsy syndromes.
Catamenial Epilepsy: Sometimes used intermittently to treat seizure clusters that occur in relation to the menstrual cycle.
Alcohol Withdrawal Syndrome: In certain international markets, it is used for the acute management of agitation and tremors during alcohol detoxification.
Severe Anxiety: Short-term management of acute anxiety states.

Dosage and Administration Protocols

Clobazam dosing is highly individualized. It is typically determined based on the patient’s weight, clinical response, and the presence of any underlying metabolic concerns.

Standard Weight-Based Dosing for LGS

Patient Weight	Starting Daily Dose	Maintenance Daily Dose (Titrated)	Maximum Daily Dose
30 kg or less	5 mg once daily	10 mg (divided twice daily)	20 mg per day
Greater than 30 kg	10 mg (divided twice daily)	20 mg (divided twice daily)	40 mg per day

Administration Notes:

Titration: Doses should be increased no more frequently than once weekly. This allows the physician to assess the patient’s tolerance and the drug’s efficacy.
Food: Clobazam can be taken with or without food.
Oral Suspension: The liquid formulation must be shaken well before administration and used with the provided dosing syringe.
Tablets: 10 mg and 20 mg tablets are scored and can be split or crushed and mixed with applesauce if the patient has difficulty swallowing.

Special Population Adjustments

Renal Impairment: No specific dose adjustment is required for mild to moderate renal impairment. However, use with caution in patients with end-stage renal disease (ESRD).
Hepatic Impairment: Clobazam is extensively metabolized by the liver. In patients with mild to moderate hepatic impairment, the starting dose should be reduced, and titration should proceed slowly. It is generally avoided in severe hepatic impairment.
Geriatric Patients: Elderly patients are more sensitive to the CNS effects. Start at 5 mg daily and titrate very slowly.
CYP2C19 Poor Metabolizers: These individuals process the active metabolite (N-desmethylclobazam) more slowly. The starting dose should be 5 mg/day, with careful monitoring for toxicity.

Clinical Efficacy and Research Results

The efficacy of Clobazam has been solidified through rigorous clinical trials, most notably the CONTAIN Trial, which remains a benchmark in pediatric neurology.

Recent Data and Outcomes (2020-2026 Focus)

Recent longitudinal studies and real-world evidence gathered between 2020 and 2026 have reaffirmed the long-term sustainability of Clobazam’s effects. Unlike many benzodiazepines, which exhibit significant “tolerance” (where the drug stops working over time), Clobazam has shown a lower rate of tolerance development in LGS patients.

Seizure Frequency Reduction: In a pivotal Phase III trial, patients taking the high-dose regimen (0.5 mg/kg/day) experienced a median reduction in drop seizure frequency of 41.2% to 68.3% compared to baseline.
Total Seizure Freedom: Clinical data suggest that approximately 12% to 15% of patients with LGS achieve complete freedom from drop seizures when Clobazam is added to their regimen.
Caregiver Global Impression (CGI): In 2022-2024 observational studies, over 70% of caregivers reported “much improved” or “very much improved” overall clinical status in pediatric patients following 12 months of Clobazam therapy.
Active Metabolite Levels: Research into N-desmethylclobazam has shown that its long half-life (t1/2 of approx. 71–82 hours) contributes to a stable “steady-state” concentration in the blood, explaining the drug’s efficacy in preventing nocturnal seizures and early morning clusters.

Safety Profile and Side Effects

BLACK BOX WARNING

RISKS FROM CONCOMITANT USE WITH OPIOIDS; ABUSE, MISUSE, AND ADDICTION; AND DEPENDENCE AND WITHDRAWAL REACTIONS.

The use of benzodiazepines, including Clobazam, with opioids may result in profound sedation, respiratory depression, coma, and death.
Clobazam exposes users to risks of abuse, misuse, and addiction, which can lead to overdose or death.
Abrupt discontinuation or rapid dosage reduction may precipitate life-threatening withdrawal reactions (e.g., seizures, hallucinations, psychosis).

Common Side Effects (Greater than 10% Frequency)

Somnolence (Sleepiness) and Sedation: The most frequently reported effect.
Pyrexia (Fever): Particularly in pediatric populations.
Lethargy and Fatigue: A general feeling of tiredness.
Drooling (Sialorrhea): Common in children with LGS.
Ataxia: Difficulty with coordination or balance.

Serious Adverse Events

Serious Skin Reactions: Rare but life-threatening reactions such as Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN) have been reported. These can occur at any time but are most likely during the first 8 weeks of treatment.
Suicidal Ideation: Like all Antiepileptic Drugs (AEDs), Clobazam can increase the risk of suicidal thoughts or behavior.
Respiratory Depression: Especially when combined with other CNS depressants.
Physical Dependence: Long-term use leads to physiological changes that require a very gradual taper to stop the drug safely.

Management Strategies

For Sedation: Administer the larger portion of the daily dose at bedtime.
For Skin Rash: Immediate Intervention Required. If any rash, mucosal blistering, or peeling occurs, the drug must be discontinued immediately, and the patient must seek emergency care.
For Withdrawal: Always use a tapering schedule (e.g., reducing the dose by 5-10 mg per week) under strict physician supervision.

Research Areas

While Clobazam is not currently a direct component of Regenerative Medicine or Stem Cell Therapy, it plays a critical role in the broader research ecosystem of Neuromodulation.

Current clinical trials (2024-2026) are investigating the synergistic effects of Clobazam when combined with Cannabidiol (CBD) and Vagus Nerve Stimulation (VNS). Researchers are looking at whether Clobazam can stabilize the neural environment enough to allow for better integration of future Cellular Therapies or gene-editing interventions (such as CRISPR-based therapies for SCN1A mutations).

Furthermore, studies are exploring the Pharmacogenomics of Clobazam—specifically how a patient’s genetic makeup affects their ability to metabolize the drug—to move toward a Precision Medicine model in epilepsy care.

Patient Management and Practical Recommendations

Effective management of a patient on Frisium/Onfi requires a collaborative approach between the specialist, the patient, and the caregiver.

Pre-treatment Tests

Genetic Testing: Screening for the CYP2C19 genotype is highly recommended to identify “Poor Metabolizers” who may require lower doses.
Baseline Metabolic Panel: Assessment of liver and kidney function (ALT, AST, Creatinine).
Neurological Baseline: Documentation of seizure types and frequency via a seizure diary.

Precautions During Treatment

Vigilance for Mood Changes: Caregivers should monitor for signs of depression, anxiety, or suicidal thoughts.
Skin Monitoring: Regular inspection of the skin for any new rashes or lesions.
Avoidance of CNS Depressants: Patients should avoid alcohol and be cautious with over-the-counter sleep aids or antihistamines.

Do’s and Don’ts

DO take the medication consistently at the same time every day.
DO report any sudden changes in mood or behavior to your physician.
DON’T crush or chew the tablets unless specified by the formulation.
DON’T stop the medication abruptly, as this can trigger severe seizures.

Legal Disclaimer

This guide is provided for informational and educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always seek the advice of a physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read in this guide. The use of the medication described herein must be under the direct supervision of a licensed healthcare professional.